Baseline clinical characteristics for the total study population. From the 240 individualsBaseline clinical qualities for

Baseline clinical characteristics for the total study population. From the 240 individuals
Baseline clinical qualities for the total study population. Of your 240 patients switched to lurasidone from other antipsychotics, 235 patients with accessible information on the PETiT scale and SF-12 assessment comprised the ITTAwad et al. BMC Psychiatry 2014, 14:53 http:biomedcentral1471-244X14Page 4 ofTable 1 Patient demographics and baseline clinical characteristicsParameter N Imply age Years, SD Gender Male Female Race Asian Black or African ETB MedChemExpress American Native Hawaiian or other Pacific Islander White Other DSM-IV Schizophrenia subtype diagnosis 295.10 Disorganized type 295.20 Catatonic form 295.30 Paranoid sort 295.60 Residual variety 295.70 Schizoaffective disorder 295.90 Undifferentiated variety Preswitch antipsychotic agent at study start off Quetiapine Risperidone Aripiprazole Ziprasidone Olanzapine Paliperidone Iloperidone Asenapine First-generation antipsychotic Remedy with concomitant lithium, valproate or lamotrigine Therapy with concomitant antidepressant Mean age (SD) at initial onset of schizophrenia or schizoaffective disorder, years Mean constructive and negative syndrome scale total score (SD) Mean clinical international impression severity score (SD)or as indicated.83 of 235 (35 ) had been treated using a preswitch sedating medication (olanzapine or quetiapine).PETiT assessmentNo. of subjects ( )43.9 (ten.9)156 (65.0 ) 84 (35.0 )1 (0.four ) 151 (62.9 ) 1 (0.4 ) 80 (33.3 ) 7 (two.9 )The mean (normal deviation [SD]) PETiT total score for all lurasidone sufferers improved from 35.0 (eight.eight) at baseline to 38.5 (9.2) at LOCF endpoint, representing a imply improvement of 3.2 (eight.5) or 9.1 (p 0.001). Improvements from baseline to LOCF endpoint in the total score, too as in the domains of adherence-related attitude (0.7 [2.6]) and psychosocial functioning (two.5 [6.9]), had been statistically important (p 0.002) for all individuals who had been switched to lurasidone (Table two). All elements of your psychosocial functioning domain (IKK-β custom synthesis activity, cognitive, and dysphoria) showed substantial improvement (p 0.002) with all the exception of social functioning, where a non-significant improvement was demonstrated.PETiT scores by preswitch antipsychotic medication4 (1.7 ) 0 125 (52.1 ) 2 (0.eight ) 89 (37.1 ) 21 (8.8 )62 (25.eight ) 51 (21.3 ) 44 (18.three ) 27 (11.3 ) 24 (ten.0 ) 9 (3.8 ) 4 (1.7 ) two (0.8 ) 17 (7.1 ) 34 (16.2 ) 104 (43.3 ) 25.1 (9.3) 68.9 (13.eight) three.7 (0.five)The variations in patients’ PETiT scores were also stratified according to the antipsychotic medication utilised before switching to lurasidone. To ensure a affordable sample size for this evaluation, preswitch antipsychotic drugs received by ten of sufferers inside the study were integrated for stratification. The medicines included quetiapine (n = 62), risperidone (n = 51), aripiprazole (n = 44), ziprasidone (n = 27), and olanzapine (n = 24). Sufferers on all of those preswitch medications except olanzapine showed statistically important improvements in total PETiT scores, as determined by imply changes from baseline to LOCF ( D): quetiapine 4.two (7.7), p = 0.011; risperidone 3.6 (7.9), p = 0.029; aripiprazole 3.4 (8.0), p = 0.010; ziprasidone 5.four (7.9), p = 0.009 (Table 3). Sufferers on these four agents also showed important improvements on the psychosocial functioning element (all p 0.05) (Table three). For sufferers switched from olanzapine, a numerical decrease inside the total PETiT score and its components was observed; however, this difference was not statistically substantial. Patients within the aripiprazole and ziprasidone preswi.